SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: majormember who wrote (2289)4/6/1999 1:16:00 PM
From: Duke  Read Replies (2) | Respond to of 4140
 
DO THESE GUYS POSE A THREAT?
>
> Privately held Refractec, Inc. said that Phase II clinical
> studies showed its non-laser corneal shaping system brought 65
> human eyes with 1 to 4.5 diopters of hyperopia to within 1 diopter
> of the attempted correction, with uncorrected visual acuity of
> 20/40 or better, at 12 months post-op. The patented device, which
> may cost doctors $40,000, uses radio-frequency energy to reshape
> the cornea; the company says it can correct low hyperopia,
> presbyopia, and eyes previously overcorrected by excimer laser
> surgery, but the procedure is done outside of the optical zone.
> Phase III studies began in February.



To: majormember who wrote (2289)4/6/1999 8:24:00 PM
From: HeyRainier  Read Replies (1) | Respond to of 4140
 
OT: It doesn't seem that the past nine years on BEAM's trading history has helped me any in providing profit-maximizing guidance. I've never seen such buying enthusiasm on a time/price basis for this stock. Since it's apparent that it's trading on a wavelength that I am unaccustomed to, I would like to decline at this time at trying to pick a top for the issue.

RT


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News